The Metabolic-Cognitive Link: Exploring the Association Between Diabetes and Alzheimer's Disease

Background: Alzheimer's Disease (AD), the leading cause of dementia, is pathologically defined by Aβ plaque accumulation and neurofibrillary tangles of hyperphosphorylated tau proteins. Type 2 Diabetes Mellitus (T2DM) is now established as a potent, modifiable risk factor for AD, sharing substantial molecular and cellular pathology that has led to the conceptualization of AD as "Type 3 Diabetes." Objectives: To detail the shared mechanisms, such as cerebral insulin resistance, impaired protein clearance, and chronic neuroinflammation, that link T2DM and AD, and to critically evaluate the translational potential of anti-diabetic medications as disease-modifying therapies for AD. Methodology: Literature synthesis of key established epidemiological cohort studies, mechanistic investigations (in vivo and in vitro), and pertinent clinical trials was performed. Results: Evidence demonstrates that T2DM promotes cerebral insulin resistance, driving tau hyperphosphorylation and synaptic loss. Dysregulated Insulin-Degrading Enzyme (IDE) activity due to competitive substrate binding (insulin versus Aβ) accelerates Aβ accumulation. Furthermore, the systemic diabetic environment (hyperglycemia and vascular damage) synergistically enhances neurodegeneration. Conclusion: The metabolic dysregulation central to diabetes is a potent and synergistic driver of AD pathology. Targeting shared metabolic vulnerabilities—particularly through incretin-based therapies (e.g., GLP-1R agonists) and other insulin-sensitizing agents—represents the most promising and translational disease-modifying strategy for AD.